Chemotherapy Resistance and Sensitivity Testing in Lung Tumors

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01570855

Enrollment

Registered

2012-04-04

Start date

2011-10-31

Completion date

2015-12-31

Last updated

2016-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Keywords

Lung cancer, chemosensitivity

Brief summary

The purpose of this study is to screen chemotherapy drugs currently used to treat lung cancer and determine the most effective treatment based on results of chemo sensitivity testing on the patients own cancer cells in the laboratory. The results of this screening will not influence the patients treatment.

Detailed description

The chemosensitivity assay will be performed on tissue obtained during the diagnostic fine needle aspiration, core biopsy, or excisional biopsy of the lung lesion. Cancer cells (Bulk of tumor) and Cancer Stem Cells (CSCs) will be isolated and expanded in the laboratory. The drug screening assay will be used to evaluate the response of the CSCs and of the cancer cells to the various chemotherapy regimens.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* suspected or confirmed diagnosis of lung cancer * undergoing a fine needle aspiration, core biopsy, or excisional biopsy for diagnosis. * Chemotherapy must be clinically indicated for treatment of the patient's qualifying disease * Patient must be at least 18 years of age * Patient must have signed an IRB approved informed consent form for the data collection study prior to entry of data into the enrollment form in the database.

Exclusion criteria

* Patient pathology shows benign pathology for sample submitted * Patient is not indicated to receive chemotherapy for their disease

Design outcomes

Primary

Measure	Time frame	Description
Tumor size	3 months	Tumor response will be evaluated (progression/regression) by CT scan at 3 months from therapy start. Clinical response to chemotherapy of lung cancer tumor cells versus lung cancer stem cells to standard of care chemo drugs will be evaluated and correlated to predicted drug by ex vivo assay.

Countries

United States

Outcome results